ArticleFrontiers in nutrition2026
Palmitoleic acid content and composition-based nutritional quality of commercial omega-7 oils and supplements.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Commercial omega-7 products vary widely in fatty acid composition and chemical form, complicating direct comparison among products. This study compared commercially available omega-7 sources using palmitoleic acid (POA; 16:1 n-7) and total omega-7, calculated as POA plus cis-vaccenic acid (18:1 n-7), as composition-based indicators of omega-7 nutritional quality. Methods: Fish oil ethyl ester (FOEE) concentrates were analyzed directly, and fatty acid methyl ester (FAME) samples prepared from high-palmitoleic algal oil, seabuckthorn oils (SBO) and powder (SBOP), macadamia oils (MO), and avocado oils (AO) were analyzed by GC-FID. Results: Marked variation was observed among products. The algal oil showed the highest POA (67.3%) and total omega-7 (70.3%). The FOEE concentrates also contained high POA (54.8-57.0%), with total omega-7 only slightly higher than POA because 18:1 n-7 was very low. MO provided moderate and consistent omega-7 levels (21.5-23.0% POA; 24.8-27.0% total omega-7), whereas AO were lower (5.6-10.0% POA; 8.9-15.9% total omega-7). SBO supplements showed the greatest variability, ranging from omega-7-rich oils (25.5-35.5% POA; 32.1-46.8% total omega-7) to supplements with low or trace omega-7 (0.2-8.3% POA; 0.2-11.1% total omega-7), reflecting differences in berry/pulp, seed oil, and blended formulations. Discussion: These results demonstrate that commercial omega-7 products are not compositionally equivalent. Based on POA and total omega-7 content, algal oil showed the highest omega-7 enrichment among triglyceride-based products, FOEE concentrates were also highly enriched in a structurally distinct ethyl ester form, MO offered intermediate and consistent omega-7 levels, and SBO products exhibited substantial variability in omega-7 composition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.